We thank Huixun Jia and Xiaodong Sun for their perspective on our study.1 The goals of this first-in-human trial were to identify safe doses of RGX-314 and an optimised protocol for advanced studies.

With nearly 1.5 million people suffering from rheumatoid and juvenile arthritis in the United States, researchers at Shriners Children's St. Louis have discovered a revolutionary way to potentially ...

The US Food and Drug Administration (FDA) has approved revakinagene taroretcel-lwey (ENCELTO) from Neurotech Pharmaceuticals ...

Traditional methods for identifying therapeutic gene targets, crucial for personalized medicine, are expensive and ...

Allogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T 'Cemacabtagene Ansegedleucel/ALLO-501' in Relapsed/Refractory Large B-Cell ...

SEOUL, South Korea--(BUSINESS WIRE)--ENCell, a leading biopharmaceutical company for cell and gene therapy CDMO and novel drug development, announced today that its investigational drug EN001 has been ...

One of the pioneers of CAR T-cell therapy, Dr. Brentjens spoke with Becker's about what the new facility means for cancer innovation, as well as on how leaders across the U.S. can best integrate CAR T ...